{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166104960",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166104960",
  "name" : "Dutch Pharmacogenetics Working Group Guideline for thioguanine and TPMT",
  "relatedDrugs" : [ {
    "objCls" : "Drug",
    "@id" : "https://www.pharmgkb.org/data/drug/PA451663",
    "@context" : "https://www.pharmgkb.org/jsonld/drug.jsonld",
    "id" : "PA451663",
    "name" : "thioguanine"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA356",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA356",
    "symbol" : "TPMT",
    "name" : "thiopurine S-methyltransferase"
  } ],
  "source" : "DPWG",
  "summaryHtml" : "<p>Select an alternative drug rather than thioguanine for intermediate and poor TPMT metabolizers.</p>",
  "textHtml" : "<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for thioguanine based on TPMT genotype [Article:<a href=\"/pmid/21412232\">21412232</a>].  They recommend selecting an alternative drug for patients carrying inactive alleles.</p><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Phenotype (Genotype) </th><th> Therapeutic Dose Recommendation </th><th> Level of Evidence </th><th> Clinical Relevance </th></tr><tr><td> IM (one inactive allele: *2, *3, *4-*18) </td><td> Select alternative drug.  Insufficient data to allow calculation of dose adjustment. </td><td> Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (S): long-standing discomfort (&gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR &gt; 6.0; neutropenia 0.5-1.0x109/l; leucopenia 1.0-2.0x109/l; thrombocytopenia 25-50x109/l; severe diarrhea. </td></tr><tr><td> PM (two inactive alleles: *2, *3, *4-*18) </td><td> Select alternative drug.  Insufficient data to allow calculation of dose adjustment. </td><td> Published case reports, well documented, and having relevant pharmacokinetic or clinical endpoints. Well documented case series. </td><td> Clinical effect (S): death; arrhythmia; unanticipated myelosuppression. </td></tr></table><ul><li>*See <a href=\"http://www.pharmgkb.org/home/dutch_pharmacogenetics_working_group.jsp\">Methods</a> or <a href=\"http://www.pharmgkb.org/pmid/18253145\">PMID: 18253145</a> for definition of \"moderate\" quality.</li><li>S: statistically significant difference.</li></ul>"
}